An international research team headed by two University of Adelaide researchers has been awarded a US$900,000 grant to help unravel the phenomenon of "DNA looping". DNA looping is responsible for controlling the expression of genes in cells. It is believed to play a key role in a number of diseases, including many cancers. The looping occurs due to the binding of proteins to different regions of the DNA. Complete news at...
Friday, April 24, 2009
Thursday, April 23, 2009
RapidArc Radiotherapy Technology Enabling Fast, Accurate Treatments For Pennsylvania Cancer Patients
RapidArc Radiotherapy Technology Enabling Fast, Accurate Treatments For Pennsylvania Cancer Patients
Two patients, both in their 70s, have become the first people in Allentown, Pennsylvania, to receive a new, faster, more precise form of radiotherapy for cancer. A 72-year-old man was treated for prostate cancer, while a 70-year-old woman received treatment for a brain tumor at the base of her skull.
Two patients, both in their 70s, have become the first people in Allentown, Pennsylvania, to receive a new, faster, more precise form of radiotherapy for cancer. A 72-year-old man was treated for prostate cancer, while a 70-year-old woman received treatment for a brain tumor at the base of her skull.
Circassia's Allergy Therapy Begins Phase II Clinical Trial In Asthma Patients
Circassia's Allergy Therapy Begins Phase II Clinical Trial In Asthma Patients
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced that it has initiated a phase II clinical study of its ToleroMune(R) technology in allergy patients with asthma. The trial builds on positive phase II results that demonstrated the potential clinical benefits of ToleroMune allergy therapy, and extends clinical investigations to those with allergy-associated asthma.
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, announced that it has initiated a phase II clinical study of its ToleroMune(R) technology in allergy patients with asthma. The trial builds on positive phase II results that demonstrated the potential clinical benefits of ToleroMune allergy therapy, and extends clinical investigations to those with allergy-associated asthma.
Subscribe to:
Posts (Atom)
